JAKs in PMR? "BACHELOR" study randomized 34pts to BARI vs PLBO Despite small sample, significant benefit at 12 wks (CRP PMR-AS < 10) for bari (78%) vs. PLBO (13%) Useful, but not for getting regulatory approval. Should have gone straight to phase 3! #ACR24 @RheumNow Abstr#0858 https://t.co/mmMs6c3AYC

• https://x.com/EBRheum/status/1857890384598155396/photo/1
• https://x.com/EBRheum/status/1857890384598155396/photo/1

LTE of deucravacitinib trials in psoriasis. Remarkable & frankly surprising (to me) persistence of benefit Very encouraging for patients who start TYKs, looks like those who respond may have prolonged benefit #ACR24 @RheumNow Abstr#0290 #ACRBest https://t.co/kao4vqpPTQ

• https://x.com/EBRheum/status/1857888161440883147/photo/1
• https://x.com/EBRheum/status/1857888161440883147/photo/1
• https://x.com/EBRheum/status/1857888161440883147/photo/1

A cohort of 9 patients with Anti-MDA5 DM with RPILD who was treated with combination of RTX, JAKi, and GCS had significantly bettery survival compared to historical cohort in this abstract! #ACR24 @RheumNow https://t.co/2t8xcYJ3UV

• https://x.com/MartinezZayasMd/status/1857838587611406427/photo/1

This is likely an oversimplification, but I've been looking for exactly this diagram Inhibiting various TYKs/JAKs corresponds to various downstream cytokine inhibition @EricFMorand does it make sense to see this as anifrolumab+ustekinumab? No? @rheumnow #ACR24 Abstr#0662 https://t.co/thti6s5TR3

• https://x.com/EBRheum/status/1857836781628174735/photo/1
• https://x.com/EBRheum/status/1857836781628174735/photo/1

Courvoisier et al. JAK-pot study analysis. Which therapies work quicker in RA? JAKi (as expected) and TNFi (what!?) faster than IL6 and abatacept. @RheumNow #ACR24 Abstr#0501 https://t.co/7DPPwHlqpP https://t.co/3mOJ62hZhp

• How Fast Do JAK-inhibitors, TNF-inhibitors, Abatacept and IL-6 Inhibitors Act i…
• https://x.com/RichardPAConway/status/1857823192204677592/photo/1

Serrano-Combarro et al. Baricitinib in RA-ILD . 72 patient case series. PFTs in picture. HRCT stable/improved in 72% over 24 months. Dyspnoea stable/improved in 90%. @RheumNow #ACR24 Abstr#0476 https://t.co/aVI2kRZkMN https://t.co/4l5GKsFKtm

• Baricitinib in Rheumatoid Arthritis - Interstitial Lung Disease. National Multi…
• https://x.com/RichardPAConway/status/1857820927368610111/photo/1

PRO-SPIRIT trial data on 1192 PsA pts showed IL-17Ai seemed better than IL-12/23i and IL-23i improving cDAPSA at 3m and as effective as TNFi and JAKi. No much differences seen at 12m. Abst#0076 #ACR24 @RheumNow https://t.co/dScwsmkDOe

• https://x.com/AdelaCastro222/status/1857819668875968932/photo/1

#0584🔬Real-World PsA Study:Tofacitinib ➡️141 pts:47% mono,53% combo;~70% on Rx @ 6mo ➡️Similar ⬆️in disease outcomes (cDAPSA LDA: 31% mono vs 21% combo; MDA ~16%). ➡️No significant differences mono v combo outcomes 🩺Tofa effective in diverse PsA population #ACR24 @RheumNow

Is biologic response different in men vs women with axSpA? A Meta-analysis of 11 studies including 11,199 axSpA pts evaluated sex-related response to bDMARDs -Male pts more likely to achieve BASDAI 50 and ASDAS low disease activity responses compared to females. #Abst0599… https://t.co/FopBLS4bF6 https://t.co/PpoZB9HwZN

• https://x.com/i/web/status/1857815900935635319
• https://x.com/AdelaCastro222/status/1857815900935635319/photo/1

Cool data from the JAK-POT study Have heard JAKs faster than TNF; perhaps not the case! If anything, TNFs outperformed the others in this study Trying not to over-read this, but supports my re-emerging preference for TNF #ACR24 @rheumnow Abstr#0501 https://t.co/NDyPwju3ds

• https://x.com/EBRheum/status/1857813881176854579/photo/1
• https://x.com/EBRheum/status/1857813881176854579/photo/1

#0501 💥 JAKi & TNFi show faster short-term RA improvement (3months) compared to IL-6i & ABA ➡️n=9590(3049 JAKi, 4606 TNFi, 1284 IL-6, 651 ABA), 14 registers 🕒 JAKi, TNFi improved CDAI, pain, function in 1st two months then stabilised 💡Long-term data needed #ACR24 @RheumNow https://t.co/4yzeAAkGjq

• https://x.com/CaoilfhionnMD/status/1857806079457136834/photo/1

SELECT-GCA Trial results show UPA 15 mg + 26-week GC taper leads to 46% sustained remission vs. 29% with placebo + 52-week taper (P=.0019). UPA15 reduced GC use (median 1615mg vs. 2882mg, P<.0001) and improved fatigue scores. Key finding: UPA15 combined with a 26-week GC… https://t.co/rdHU3GuOwc https://t.co/oMS7x46sIB

• https://x.com/i/web/status/1857803311363002426
• https://x.com/synovialjoints/status/1857803311363002426/photo/1